DLA
PFE icon

Douglas Lane & Associates’s Pfizer PFE Stock Holding History

Douglas Lane & Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$582K Sell
24,170
-11,483
-32% -$300K 0.01% 183
2026
Q1 		$1M Sell
35,653
-1,206
-3% -$32.1K 0.01% 154
2025
Q4 		$918K Sell
36,859
-2,639
-7% -$66.5K 0.01% 160
2025
Q3 		$1.01M Sell
39,498
-4,842
-11% -$120K 0.01% 157
2025
Q2 		$1.07M Buy
44,340
+887
+2% +$20.7K 0.02% 154
2025
Q1 		$1.1M Buy
43,453
+7,702
+22% +$202K 0.02% 157
2024
Q4 		$948K Sell
35,751
-1,818
-5% -$49.3K 0.01% 161
2024
Q3 		$1.09M Sell
37,569
-5,642
-13% -$165K 0.01% 156
2024
Q2 		$1.21M Sell
43,211
-3,466
-7% -$95.4K 0.02% 155
2024
Q1 		$1.3M Buy
46,677
+704
+2% +$19.5K 0.02% 153
2023
Q4 		$1.32M Sell
45,973
-2,969
-6% -$89.8K 0.02% 153
2023
Q3 		$1.62M Buy
48,942
+2,363
+5% +$83.6K 0.03% 139
2023
Q2 		$1.71M Sell
46,579
-568
-1% -$22.1K 0.03% 137
2023
Q1 		$1.92M Buy
47,147
+1,282
+3% +$55.4K 0.03% 136
2022
Q4 		$2.35M Sell
45,865
-1,103
-2% -$52.9K 0.04% 133
2022
Q3 		$2.06M Buy
46,968
+842
+2% +$40.9K 0.04% 131
2022
Q2 		$2.42M Buy
46,126
+1,234
+3% +$62.9K 0.04% 129
2022
Q1 		$2.32M Buy
44,892
+537
+1% +$27.9K 0.03% 133
2021
Q4 		$2.62M Sell
44,355
-273
-0.6% -$13.5K 0.03% 134
2021
Q3 		$1.92M Sell
44,628
-2,470
-5% -$109K 0.03% 141
2021
Q2 		$1.84M Buy
47,098
+976
+2% +$38K 0.03% 138
2021
Q1 		$1.67M Sell
46,122
-4,881
-10% -$173K 0.03% 136
2020
Q4 		$1.88M Sell
51,003
-3,874
-7% -$142K 0.03% 128
2020
Q3 		$1.91M Sell
54,877
-731
-1% -$25.6K 0.04% 125
2020
Q2 		$1.73M Sell
55,608
-5,138
-8% -$175K 0.04% 123
2020
Q1 		$1.88M Sell
60,746
-3,118
-5% -$106K 0.05% 121
2019
Q4 		$2.37M Sell
63,864
-2,246
-3% -$80K 0.04% 123
2019
Q3 		$2.25M Sell
66,110
-1,377
-2% -$50.1K 0.04% 124
2019
Q2 		$2.77M Sell
67,487
-403
-0.6% -$16K 0.05% 121
2019
Q1 		$2.74M Buy
67,890
+744
+1% +$29.8K 0.06% 121
2018
Q4 		$2.78M Sell
67,146
-2,070
-3% -$85.9K 0.07% 117
2018
Q3 		$2.89M Buy
69,216
+1,888
+3% +$72.7K 0.06% 120
2018
Q2 		$2.32M Sell
67,328
-1,241
-2% -$42.4K 0.05% 124
2018
Q1 		$2.31M Sell
68,569
-6,381
-9% -$219K 0.05% 118
2017
Q4 		$2.58M Sell
74,950
-4,123
-5% -$141K 0.05% 116
2017
Q3 		$2.68M Sell
79,073
-1,706
-2% -$54.8K 0.06% 118
2017
Q2 		$2.57M Sell
80,779
-3,326
-4% -$105K 0.06% 126
2017
Q1 		$2.73M Sell
84,105
-5,551
-6% -$175K 0.07% 124
2016
Q4 		$2.76M Sell
89,656
-1,506
-2% -$46K 0.07% 127
2016
Q3 		$2.93M Sell
91,162
-1,430
-2% -$47.8K 0.08% 131
2016
Q2 		$3.09M Sell
92,592
-1,678
-2% -$53.6K 0.09% 131
2016
Q1 		$2.65M Buy
+94,270
New +$2.69M 0.07% 138

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Douglas Lane & Associates's PFE Position: Q2 2026 in Review

Douglas Lane & Associates reduced its Pfizer (PFE) stake by 32% in Q2 2026, selling an estimated $300K and leaving 24,170 shares worth $582K. The position accounts for 0.01% of the portfolio, ranked #183.

Douglas Lane & Associates first reported a position in PFE in Q1 2016 and has held it in 42 quarters since. The position peaked at $3.09M in Q2 2016. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Douglas Lane & Associates held 24,170 shares of Pfizer worth $582K as of Q2 2026.
  • Douglas Lane & Associates sold 11,483 Pfizer shares in Q2 2026, an estimated $300K.
  • Pfizer made up 0.01% of Douglas Lane & Associates's portfolio in Q2 2026, its #183 holding.
  • Douglas Lane & Associates first reported a position in Pfizer in Q1 2016 and has held it in 42 quarters since.
  • Douglas Lane & Associates's Pfizer position peaked at $3.09M in Q2 2016.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Douglas Lane & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.